img

Global Influenza Vaccination Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Influenza Vaccination Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Influenza (flu) is a contagious respiratory disease caused by influenza viruses that infect the respiratory tract (nose, throat, and lungs) in humans. The symptoms and complications of flu are more severe than common cold. The symptoms associated with influenza may include fever, headache, malaise, cough, sore throat, nasal congestion, and body aches. Influenza vaccine can prevent illness and death caused
Due to the COVID-19 pandemic, the global Influenza Vaccination market size was US$ 3501.6 million in 2022 and is forecast to a readjusted size of US$ 4872.9 million by 2034 with a CAGR of 4.8% during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Egg Based accounting for % of the Influenza Vaccination global market in 2022, is projected to value US$ million by 2034, growing at a revised % CAGR from 2024 to 2034. While Hospitals segment is altered to an % CAGR throughout this forecast period.
Stringent regulatory framework along with the low accessibility of the product in the developing countries may restrain the market growth.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Influenza Vaccination market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Influenza Vaccination market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Influenza Vaccination market. Readers of the report can become informed about current and future trends of the global Influenza Vaccination market and how they will impact market growth during the forecast period.



By Company


Abbott (U.S.)
AstraZeneca (Europe)
BioCryst Pharmaceuticals (U.S.)
Novartis (Europe)
DAIICHI SANKYO COMPANY (Asia Pacific)
GlaxoSmithKline (Europe)
Hualan Biological Engineering (Asia Pacific)
Mitsubishi Tanabe Pharma (Asia Pacific)
F. Hoffmann-La Roche (Europe)
Sanofi (Europe)
Segment by Type
Egg Based
Cell Culture
Recombinant

Segment by Application


Hospitals
Research Organizations
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on.
Chapter 2Revenue of Influenza Vaccination in global and regional level.
Chapter 3Detailed analysis of Influenza Vaccination companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8Asia Pacific by type, by application and by region, revenue for each segment.
Chapter 9Latin America by type, by application and by country, revenue for each segment.
Chapter 10Middle East and Africa, by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Influenza Vaccination revenue, gross margin, and recent development, etc.
Chapter 12Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13Research Findings and Conclusion

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Influenza Vaccination Market Size Growth Rate by Type: 2018 VS 2022 VS 2034
1.2.2 Egg Based
1.2.3 Cell Culture
1.2.4 Recombinant
1.3 Market by Application
1.3.1 Global Influenza Vaccination Market Growth Rate by Application: 2018 VS 2022 VS 2034
1.3.2 Hospitals
1.3.3 Research Organizations
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Market Perspective
2.1 Global Influenza Vaccination Market Size (2018-2034)
2.2 Influenza Vaccination Market Size across Key Geographies Worldwide: 2018 VS 2022 VS 2034
2.3 Global Influenza Vaccination Market Size by Region (2018-2024)
2.4 Global Influenza Vaccination Market Size Forecast by Region (2024-2034)
2.5 Global Top 10 Influenza Vaccination Countries Ranking by Market Size
3 Influenza Vaccination Competitive by Company
3.1 Global Influenza Vaccination Revenue by Players
3.1.1 Global Influenza Vaccination Revenue by Players (2018-2024)
3.1.2 Global Influenza Vaccination Market Share by Players (2018-2024)
3.2 Global Influenza Vaccination Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Covered: Ranking by Influenza Vaccination Revenue
3.4 Global Influenza Vaccination Market Concentration Ratio
3.4.1 Global Influenza Vaccination Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Influenza Vaccination Revenue in 2022
3.5 Global Key Players of Influenza Vaccination Head office and Area Served
3.6 Global Key Players of Influenza Vaccination, Product and Application
3.7 Global Key Players of Influenza Vaccination, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Influenza Vaccination Breakdown Data by Type
4.1 Global Influenza Vaccination Historic Revenue by Type (2018-2024)
4.2 Global Influenza Vaccination Forecasted Revenue by Type (2024-2034)
5 Global Influenza Vaccination Breakdown Data by Application
5.1 Global Influenza Vaccination Historic Market Size by Application (2018-2024)
5.2 Global Influenza Vaccination Forecasted Market Size by Application (2024-2034)
6 North America
6.1 North America Influenza Vaccination Revenue by Company (2021-2024)
6.2 North America Influenza Vaccination Revenue by Type (2018-2034)
6.3 North America Influenza Vaccination Revenue by Application (2018-2034)
6.4 North America Influenza Vaccination Revenue by Country (2018-2034)
6.4.1 U.S.
6.4.2 Canada
7 Europe
7.1 Europe Influenza Vaccination Revenue by Company (2021-2024)
7.2 Europe Influenza Vaccination Revenue by Type (2018-2034)
7.3 Europe Influenza Vaccination Revenue by Application (2018-2034)
7.4 Europe Influenza Vaccination Revenue by Country (2018-2034)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
8 Asia Pacific
8.1 Asia Pacific Influenza Vaccination Revenue by Company (2021-2024)
8.2 Asia Pacific Influenza Vaccination Revenue by Type (2018-2034)
8.3 Asia Pacific Influenza Vaccination Revenue by Application (2018-2034)
8.4 Asia Pacific Influenza Vaccination Revenue by Region (2018-2034)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 India
8.4.5 Australia
8.4.6 Taiwan
8.4.7 Indonesia
8.4.8 Thailand
8.4.9 Malaysia
8.4.10 Philippines
8.4.11 Vietnam
9 Latin America
9.1 Latin America Influenza Vaccination Revenue by Company (2021-2024)
9.2 Latin America Influenza Vaccination Revenue by Type (2018-2034)
9.3 Latin America Influenza Vaccination Revenue by Application (2018-2034)
9.4 Latin America Influenza Vaccination Revenue by Country (2018-2034)
9.4.1 Mexico
9.4.2 Brazil
9.4.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Influenza Vaccination Revenue by Company (2021-2024)
10.2 Middle East and Africa Influenza Vaccination Revenue by Type (2018-2034)
10.3 Middle East and Africa Influenza Vaccination Revenue by Application (2018-2034)
10.4 Middle East and Africa Influenza Vaccination Revenue by Country (2018-2034)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 U.A.E
11 Company Profiles
11.1 Abbott (U.S.)
11.1.1 Abbott (U.S.) Company Details
11.1.2 Abbott (U.S.) Business Overview
11.1.3 Abbott (U.S.) Influenza Vaccination Products and Services
11.1.4 Abbott (U.S.) Influenza Vaccination Revenue in Influenza Vaccination Business (2018-2024)
11.1.5 Abbott (U.S.) Influenza Vaccination SWOT Analysis
11.1.6 Abbott (U.S.) Recent Development
11.2 AstraZeneca (Europe)
11.2.1 AstraZeneca (Europe) Company Details
11.2.2 AstraZeneca (Europe) Business Overview
11.2.3 AstraZeneca (Europe) Influenza Vaccination Products and Services
11.2.4 AstraZeneca (Europe) Influenza Vaccination Revenue in Influenza Vaccination Business (2018-2024)
11.2.5 AstraZeneca (Europe) Influenza Vaccination SWOT Analysis
11.2.6 AstraZeneca (Europe) Recent Development
11.3 BioCryst Pharmaceuticals (U.S.)
11.3.1 BioCryst Pharmaceuticals (U.S.) Company Details
11.3.2 BioCryst Pharmaceuticals (U.S.) Business Overview
11.3.3 BioCryst Pharmaceuticals (U.S.) Influenza Vaccination Products and Services
11.3.4 BioCryst Pharmaceuticals (U.S.) Influenza Vaccination Revenue in Influenza Vaccination Business (2018-2024)
11.3.5 BioCryst Pharmaceuticals (U.S.) Influenza Vaccination SWOT Analysis
11.3.6 BioCryst Pharmaceuticals (U.S.) Recent Development
11.4 Novartis (Europe)
11.4.1 Novartis (Europe) Company Details
11.4.2 Novartis (Europe) Business Overview
11.4.3 Novartis (Europe) Influenza Vaccination Products and Services
11.4.4 Novartis (Europe) Influenza Vaccination Revenue in Influenza Vaccination Business (2018-2024)
11.4.5 Novartis (Europe) Influenza Vaccination SWOT Analysis
11.4.6 Novartis (Europe) Recent Development
11.5 DAIICHI SANKYO COMPANY (Asia Pacific)
11.5.1 DAIICHI SANKYO COMPANY (Asia Pacific) Company Details
11.5.2 DAIICHI SANKYO COMPANY (Asia Pacific) Business Overview
11.5.3 DAIICHI SANKYO COMPANY (Asia Pacific) Influenza Vaccination Products and Services
11.5.4 DAIICHI SANKYO COMPANY (Asia Pacific) Influenza Vaccination Revenue in Influenza Vaccination Business (2018-2024)
11.5.5 DAIICHI SANKYO COMPANY (Asia Pacific) Influenza Vaccination SWOT Analysis
11.5.6 DAIICHI SANKYO COMPANY (Asia Pacific) Recent Development
11.6 GlaxoSmithKline (Europe)
11.6.1 GlaxoSmithKline (Europe) Company Details
11.6.2 GlaxoSmithKline (Europe) Business Overview
11.6.3 GlaxoSmithKline (Europe) Influenza Vaccination Products and Services
11.6.4 GlaxoSmithKline (Europe) Influenza Vaccination Revenue in Influenza Vaccination Business (2018-2024)
11.6.5 GlaxoSmithKline (Europe) Influenza Vaccination SWOT Analysis
11.6.6 GlaxoSmithKline (Europe) Recent Development
11.7 Hualan Biological Engineering (Asia Pacific)
11.7.1 Hualan Biological Engineering (Asia Pacific) Company Details
11.7.2 Hualan Biological Engineering (Asia Pacific) Business Overview
11.7.3 Hualan Biological Engineering (Asia Pacific) Influenza Vaccination Products and Services
11.7.4 Hualan Biological Engineering (Asia Pacific) Influenza Vaccination Revenue in Influenza Vaccination Business (2018-2024)
11.7.5 Hualan Biological Engineering (Asia Pacific) Influenza Vaccination SWOT Analysis
11.7.6 Hualan Biological Engineering (Asia Pacific) Recent Development
11.8 Mitsubishi Tanabe Pharma (Asia Pacific)
11.8.1 Mitsubishi Tanabe Pharma (Asia Pacific) Company Details
11.8.2 Mitsubishi Tanabe Pharma (Asia Pacific) Business Overview
11.8.3 Mitsubishi Tanabe Pharma (Asia Pacific) Influenza Vaccination Products and Services
11.8.4 Mitsubishi Tanabe Pharma (Asia Pacific) Influenza Vaccination Revenue in Influenza Vaccination Business (2018-2024)
11.8.5 Mitsubishi Tanabe Pharma (Asia Pacific) Influenza Vaccination SWOT Analysis
11.8.6 Mitsubishi Tanabe Pharma (Asia Pacific) Recent Development
11.9 F. Hoffmann-La Roche (Europe)
11.9.1 F. Hoffmann-La Roche (Europe) Company Details
11.9.2 F. Hoffmann-La Roche (Europe) Business Overview
11.9.3 F. Hoffmann-La Roche (Europe) Influenza Vaccination Products and Services
11.9.4 F. Hoffmann-La Roche (Europe) Influenza Vaccination Revenue in Influenza Vaccination Business (2018-2024)
11.9.5 F. Hoffmann-La Roche (Europe) Influenza Vaccination SWOT Analysis
11.9.6 F. Hoffmann-La Roche (Europe) Recent Development
11.10 Sanofi (Europe)
11.10.1 Sanofi (Europe) Company Details
11.10.2 Sanofi (Europe) Business Overview
11.10.3 Sanofi (Europe) Influenza Vaccination Products and Services
11.10.4 Sanofi (Europe) Influenza Vaccination Revenue in Influenza Vaccination Business (2018-2024)
11.10.5 Sanofi (Europe) Influenza Vaccination SWOT Analysis
11.10.6 Sanofi (Europe) Recent Development
12 Influenza Vaccination Market Dynamics
12.1 Influenza Vaccination Industry Trends
12.2 Influenza Vaccination Market Drivers
12.3 Influenza Vaccination Market Challenges
12.4 Influenza Vaccination Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details

List of Figure

List of Tables
Table 1. Global Influenza Vaccination Market Size Growth Rate (CAGR) by Type (US$ Million), 2018 VS 2022 VS 2034
Table 2. Key Players of Egg Based
Table 3. Key Players of Cell Culture
Table 4. Key Players of Recombinant
Table 5. Global Influenza Vaccination Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2034
Table 6. Global Influenza Vaccination Market Size (US$ Million) Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2034
Table 7. Global Influenza Vaccination Revenue by Region (2018-2024) & (US$ Million)
Table 8. Global Influenza Vaccination Revenue Forecast by Region (2024-2034) & (US$ Million)
Table 9. Global Influenza Vaccination Market Size of Top 10 Countries, 2018 VS 2022 VS 2034, (US$ Million)
Table 10. Global Influenza Vaccination Revenue by Players (2018-2024) & (US$ Million)
Table 11. Global Influenza Vaccination Market Share by Players (2018-2024)
Table 12. Global Top Influenza Vaccination Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Influenza Vaccination as of 2022)
Table 13. Ranking of Global Top Influenza Vaccination Companies by Revenue (US$ Million) in 2022
Table 14. Global 5 Largest Players Market Share by Influenza Vaccination Revenue (CR5 and HHI) & (2018-2024)
Table 15. Global Key Players of Influenza Vaccination, Headquarters and Area Served
Table 16. Global Key Players of Influenza Vaccination, Product and Application
Table 17. Global Key Players of Influenza Vaccination, Date of Enter into This Industry
Table 18. Mergers & Acquisitions, Expansion Plans
Table 19. Global Influenza Vaccination Market Size by Type (2018-2024) & (US$ Million)
Table 20. Global Influenza Vaccination Revenue Market Share by Type (2018-2024)
Table 21. Global Influenza Vaccination Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 22. Global Influenza Vaccination Revenue Market Share by Type (2024-2034)
Table 23. Global Influenza Vaccination Market Size by Application (2018-2024) & (US$ Million)
Table 24. Global Influenza Vaccination Revenue Market Share by Application (2018-2024)
Table 25. Global Influenza Vaccination Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 26. Global Influenza Vaccination Revenue Market Share by Application (2024-2034)
Table 27. North America Influenza Vaccination Revenue by Company (2021-2024) & (US$ Million)
Table 28. North America Influenza Vaccination Revenue by Type (2018-2024) & (US$ Million)
Table 29. North America Influenza Vaccination Revenue by Type (2024-2034) & (US$ Million)
Table 30. North America Influenza Vaccination Revenue by Application (2018-2024) & (US$ Million)
Table 31. North America Influenza Vaccination Revenue by Application (2024-2034) & (US$ Million)
Table 32. North America Influenza Vaccination Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 33. North America Influenza Vaccination Revenue by Country (2018-2024) & (US$ Million)
Table 34. North America Influenza Vaccination Revenue by Country (2024-2034) & (US$ Million)
Table 35. Europe Influenza Vaccination Revenue by Company (2021-2024) & (US$ Million)
Table 36. Europe Influenza Vaccination Revenue by Type (2018-2024) & (US$ Million)
Table 37. Europe Influenza Vaccination Revenue by Type (2024-2034) & (US$ Million)
Table 38. Europe Influenza Vaccination Revenue by Application (2018-2024) & (US$ Million)
Table 39. Europe Influenza Vaccination Revenue by Application (2024-2034) & (US$ Million)
Table 40. Europe Influenza Vaccination Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 41. Europe Influenza Vaccination Revenue by Country (2018-2024) & (US$ Million)
Table 42. Europe Influenza Vaccination Revenue by Country (2024-2034) & (US$ Million)
Table 43. Asia Pacific Influenza Vaccination Revenue by Company (2021-2024) & (US$ Million)
Table 44. Asia Pacific Influenza Vaccination Revenue by Type (2018-2024) & (US$ Million)
Table 45. Asia Pacific Influenza Vaccination Revenue by Type (2024-2034) & (US$ Million)
Table 46. Asia Pacific Influenza Vaccination Revenue by Application (2018-2024) & (US$ Million)
Table 47. Asia Pacific Influenza Vaccination Revenue by Application (2024-2034) & (US$ Million)
Table 48. Asia-Pacific Influenza Vaccination Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2034
Table 49. Asia Pacific Influenza Vaccination Revenue by Region (2018-2024) & (US$ Million)
Table 50. Asia Pacific Influenza Vaccination Revenue by Region (2024-2034) & (US$ Million)
Table 51. Latin America Influenza Vaccination Revenue by Company (2021-2024) & (US$ Million)
Table 52. Latin America Influenza Vaccination Revenue by Type (2018-2024) & (US$ Million)
Table 53. Latin America Influenza Vaccination Revenue by Type (2024-2034) & (US$ Million)
Table 54. Latin America Influenza Vaccination Revenue by Application (2018-2024) & (US$ Million)
Table 55. Latin America Influenza Vaccination Revenue by Application (2024-2034) & (US$ Million)
Table 56. Latin America Influenza Vaccination Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 57. Latin America Influenza Vaccination Revenue by Country (2018-2024) & (US$ Million)
Table 58. Latin America Influenza Vaccination Revenue by Country (2024-2034) & (US$ Million)
Table 59. Middle East and Africa Influenza Vaccination Revenue by Company (2021-2024) & (US$ Million)
Table 60. Middle East and Africa Influenza Vaccination Revenue by Type (2018-2024) & (US$ Million)
Table 61. Middle East and Africa Influenza Vaccination Revenue by Type (2024-2034) & (US$ Million)
Table 62. Middle East and Africa Influenza Vaccination Revenue by Application (2018-2024) & (US$ Million)
Table 63. Middle East and Africa Influenza Vaccination Revenue by Application (2024-2034) & (US$ Million)
Table 64. Middle East and Africa Influenza Vaccination Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 65. Middle East and Africa Influenza Vaccination Revenue by Country (2018-2024) & (US$ Million)
Table 66. Middle East and Africa Influenza Vaccination Revenue by Country (2024-2034) & (US$ Million)
Table 67. Abbott (U.S.) Company Details
Table 68. Abbott (U.S.) Business Overview
Table 69. Abbott (U.S.) Influenza Vaccination Product and Services
Table 70. Abbott (U.S.) Influenza Vaccination Revenue in Influenza Vaccination Business (2018-2024) & (US$ Million)
Table 71. Abbott (U.S.) Influenza Vaccination SWOT Analysis
Table 72. Abbott (U.S.) Recent Development
Table 73. AstraZeneca (Europe) Company Details
Table 74. AstraZeneca (Europe) Business Overview
Table 75. AstraZeneca (Europe) Influenza Vaccination Product and Services
Table 76. AstraZeneca (Europe) Influenza Vaccination Revenue in Influenza Vaccination Business (2018-2024) & (US$ Million)
Table 77. AstraZeneca (Europe) Influenza Vaccination SWOT Analysis
Table 78. AstraZeneca (Europe) Recent Development
Table 79. BioCryst Pharmaceuticals (U.S.) Company Details
Table 80. BioCryst Pharmaceuticals (U.S.) Business Overview
Table 81. BioCryst Pharmaceuticals (U.S.) Influenza Vaccination Product and Services
Table 82. BioCryst Pharmaceuticals (U.S.) Influenza Vaccination Revenue in Influenza Vaccination Business (2018-2024) & (US$ Million)
Table 83. BioCryst Pharmaceuticals (U.S.) Influenza Vaccination SWOT Analysis
Table 84. BioCryst Pharmaceuticals (U.S.) Recent Development
Table 85. Novartis (Europe) Company Details
Table 86. Novartis (Europe) Business Overview
Table 87. Novartis (Europe) Influenza Vaccination Product and Services
Table 88. Novartis (Europe) Influenza Vaccination Revenue in Influenza Vaccination Business (2018-2024) & (US$ Million)
Table 89. Novartis (Europe) Influenza Vaccination SWOT Analysis
Table 90. Novartis (Europe) Recent Development
Table 91. DAIICHI SANKYO COMPANY (Asia Pacific) Company Details
Table 92. DAIICHI SANKYO COMPANY (Asia Pacific) Business Overview
Table 93. DAIICHI SANKYO COMPANY (Asia Pacific) Influenza Vaccination Product and Services
Table 94. DAIICHI SANKYO COMPANY (Asia Pacific) Influenza Vaccination Revenue in Influenza Vaccination Business (2018-2024) & (US$ Million)
Table 95. DAIICHI SANKYO COMPANY (Asia Pacific) Influenza Vaccination SWOT Analysis
Table 96. DAIICHI SANKYO COMPANY (Asia Pacific) Recent Development
Table 97. GlaxoSmithKline (Europe) Company Details
Table 98. GlaxoSmithKline (Europe) Business Overview
Table 99. GlaxoSmithKline (Europe) Influenza Vaccination Product and Services
Table 100. GlaxoSmithKline (Europe) Influenza Vaccination Revenue in Influenza Vaccination Business (2018-2024) & (US$ Million)
Table 101. GlaxoSmithKline (Europe) Influenza Vaccination SWOT Analysis
Table 102. GlaxoSmithKline (Europe) Recent Development
Table 103. Hualan Biological Engineering (Asia Pacific) Company Details
Table 104. Hualan Biological Engineering (Asia Pacific) Business Overview
Table 105. Hualan Biological Engineering (Asia Pacific) Influenza Vaccination Product and Services
Table 106. Hualan Biological Engineering (Asia Pacific) Influenza Vaccination Revenue in Influenza Vaccination Business (2018-2024) & (US$ Million)
Table 107. Hualan Biological Engineering (Asia Pacific) Influenza Vaccination SWOT Analysis
Table 108. Hualan Biological Engineering (Asia Pacific) Recent Development
Table 109. Mitsubishi Tanabe Pharma (Asia Pacific) Company Details
Table 110. Mitsubishi Tanabe Pharma (Asia Pacific) Business Overview
Table 111. Mitsubishi Tanabe Pharma (Asia Pacific) Influenza Vaccination Product and Services
Table 112. Mitsubishi Tanabe Pharma (Asia Pacific) Influenza Vaccination Revenue in Influenza Vaccination Business (2018-2024) & (US$ Million)
Table 113. Mitsubishi Tanabe Pharma (Asia Pacific) Influenza Vaccination SWOT Analysis
Table 114. Mitsubishi Tanabe Pharma (Asia Pacific) Recent Development
Table 115. F. Hoffmann-La Roche (Europe) Company Details
Table 116. F. Hoffmann-La Roche (Europe) Business Overview
Table 117. F. Hoffmann-La Roche (Europe) Influenza Vaccination Product and Services
Table 118. F. Hoffmann-La Roche (Europe) Influenza Vaccination Revenue in Influenza Vaccination Business (2018-2024) & (US$ Million)
Table 119. F. Hoffmann-La Roche (Europe) Influenza Vaccination SWOT Analysis
Table 120. F. Hoffmann-La Roche (Europe) Recent Development
Table 121. Sanofi (Europe) Company Details
Table 122. Sanofi (Europe) Business Overview
Table 123. Sanofi (Europe) Influenza Vaccination Product and Services
Table 124. Sanofi (Europe) Influenza Vaccination Revenue in Influenza Vaccination Business (2018-2024) & (US$ Million)
Table 125. Sanofi (Europe) Influenza Vaccination SWOT Analysis
Table 126. Sanofi (Europe) Recent Development
Table 127. Influenza Vaccination Market Trends
Table 128. Influenza Vaccination Market Drivers
Table 129. Influenza Vaccination Market Challenges
Table 130. Influenza Vaccination Market Restraints
Table 131. Research Programs/Design for This Report
Table 132. Key Data Information from Secondary Sources
Table 133. Key Data Information from Primary Sources
List of Figures
Figure 1. Influenza Vaccination Product Picture
Figure 2. Global Influenza Vaccination Market Size by Type (US$ Million): 2018 VS 2022 VS 2034
Figure 3. Global Influenza Vaccination Market Share by Type: 2022 VS 2034
Figure 4. Egg Based Features
Figure 5. Cell Culture Features
Figure 6. Recombinant Features
Figure 7. Global Influenza Vaccination Market Size by Application (US$ Million): 2018 VS 2022 VS 2034
Figure 8. Global Influenza Vaccination Market Share by Application: 2022 VS 2034
Figure 9. Hospitals
Figure 10. Research Organizations
Figure 11. Influenza Vaccination Report Years Considered
Figure 12. Global Influenza Vaccination Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 13. Global Influenza Vaccination Market Size 2018-2034 (US$ Million)
Figure 14. Global Influenza Vaccination Market Size Market Share by Region: 2022 VS 2034
Figure 15. Global Influenza Vaccination Revenue Market Share by Region in 2018 VS 2022
Figure 16. Global Influenza Vaccination Revenue Market Share Forecast by Region (2024-2034)
Figure 17. Global Top 10 Influenza Vaccination Countries Ranking by Market Size (US$ Million) in 2022
Figure 18. Global Influenza Vaccination Market Size of Top 10 Countries, 2018 VS 2022 VS 2034, (US$ Million)
Figure 19. Global Influenza Vaccination Market Share by Players in 2022
Figure 20. Global Top Influenza Vaccination Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Influenza Vaccination as of 2022)
Figure 21. The Top 10 and 5 Players Market Share by Influenza Vaccination Revenue in 2022
Figure 22. North America Influenza Vaccination Revenue Market Share by Company in 2022
Figure 23. North America Influenza Vaccination Revenue Market Share by Type (2018-2034)
Figure 24. North America Influenza Vaccination Revenue Market Share by Application (2018-2034)
Figure 25. North America Influenza Vaccination Revenue Share by Country (2018-2034)
Figure 26. U.S. Influenza Vaccination Revenue (2018-2034) & (US$ Million)
Figure 27. Canada Influenza Vaccination Revenue (2018-2034) & (US$ Million)
Figure 28. Europe Influenza Vaccination Revenue Market Share by Company in 2022
Figure 29. Europe Influenza Vaccination Revenue Market Share by Type (2018-2034)
Figure 30. Europe Influenza Vaccination Revenue Market Share by Application (2018-2034)
Figure 31. Europe Influenza Vaccination Revenue Share by Country (2018-2034)
Figure 32. Germany Influenza Vaccination Revenue (2018-2034) & (US$ Million)
Figure 33. France Influenza Vaccination Revenue (2018-2034) & (US$ Million)
Figure 34. U.K. Influenza Vaccination Revenue (2018-2034) & (US$ Million)
Figure 35. Italy Influenza Vaccination Revenue (2018-2034) & (US$ Million)
Figure 36. Russia Influenza Vaccination Revenue (2018-2034) & (US$ Million)
Figure 37. Asia Pacific Influenza Vaccination Revenue Market Share by Company in 2022
Figure 38. Asia Pacific Influenza Vaccination Revenue Market Share by Type (2018-2034)
Figure 39. Asia Pacific Influenza Vaccination Revenue Market Share by Application (2018-2034)
Figure 40. Asia Pacific Influenza Vaccination Revenue Share by Region (2018-2034)
Figure 41. China Influenza Vaccination Revenue (2018-2034) & (US$ Million)
Figure 42. Japan Influenza Vaccination Revenue (2018-2034) & (US$ Million)
Figure 43. South Korea Influenza Vaccination Revenue (2018-2034) & (US$ Million)
Figure 44. India Influenza Vaccination Revenue (2018-2034) & (US$ Million)
Figure 45. Australia Influenza Vaccination Revenue (2018-2034) & (US$ Million)
Figure 46. Taiwan Influenza Vaccination Revenue (2018-2034) & (US$ Million)
Figure 47. Indonesia Influenza Vaccination Revenue (2018-2034) & (US$ Million)
Figure 48. Thailand Influenza Vaccination Revenue (2018-2034) & (US$ Million)
Figure 49. Malaysia Influenza Vaccination Revenue (2018-2034) & (US$ Million)
Figure 50. Philippines Influenza Vaccination Revenue (2018-2034) & (US$ Million)
Figure 51. Vietnam Influenza Vaccination Revenue (2018-2034) & (US$ Million)
Figure 52. Latin America Influenza Vaccination Revenue Market Share by Company in 2022
Figure 53. Latin America Influenza Vaccination Revenue Market Share by Type (2018-2034)
Figure 54. Latin America Influenza Vaccination Revenue Market Share by Application (2018-2034)
Figure 55. Latin America Influenza Vaccination Revenue Share by Country (2018-2034)
Figure 56. Mexico Influenza Vaccination Revenue (2018-2034) & (US$ Million)
Figure 57. Brazil Influenza Vaccination Revenue (2018-2034) & (US$ Million)
Figure 58. Argentina Influenza Vaccination Revenue (2018-2034) & (US$ Million)
Figure 59. Middle East and Africa Influenza Vaccination Revenue Market Share by Company in 2022
Figure 60. Middle East and Africa Influenza Vaccination Revenue Market Share by Type (2018-2034)
Figure 61. Middle East and Africa Influenza Vaccination Revenue Market Share by Application (2018-2034)
Figure 62. Middle East and Africa Influenza Vaccination Revenue Share by Country (2018-2034)
Figure 63. Turkey Influenza Vaccination Revenue (2018-2034) & (US$ Million)
Figure 64. Saudi Arabia Influenza Vaccination Revenue (2018-2034) & (US$ Million)
Figure 65. U.A.E Influenza Vaccination Revenue (2018-2034) & (US$ Million)
Figure 66. Abbott (U.S.) Revenue Growth Rate in Influenza Vaccination Business (2018-2024)
Figure 67. AstraZeneca (Europe) Revenue Growth Rate in Influenza Vaccination Business (2018-2024)
Figure 68. BioCryst Pharmaceuticals (U.S.) Revenue Growth Rate in Influenza Vaccination Business (2018-2024)
Figure 69. Novartis (Europe) Revenue Growth Rate in Influenza Vaccination Business (2018-2024)
Figure 70. DAIICHI SANKYO COMPANY (Asia Pacific) Revenue Growth Rate in Influenza Vaccination Business (2018-2024)
Figure 71. GlaxoSmithKline (Europe) Revenue Growth Rate in Influenza Vaccination Business (2018-2024)
Figure 72. Hualan Biological Engineering (Asia Pacific) Revenue Growth Rate in Influenza Vaccination Business (2018-2024)
Figure 73. Mitsubishi Tanabe Pharma (Asia Pacific) Revenue Growth Rate in Influenza Vaccination Business (2018-2024)
Figure 74. F. Hoffmann-La Roche (Europe) Revenue Growth Rate in Influenza Vaccination Business (2018-2024)
Figure 75. Sanofi (Europe) Revenue Growth Rate in Influenza Vaccination Business (2018-2024)
Figure 76. Bottom-up and Top-down Approaches for This Report
Figure 77. Data Triangulation
Figure 78. Key Executives Interviewed